Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease
Identifieur interne : 006329 ( Main/Exploration ); précédent : 006328; suivant : 006330Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease
Auteurs : J. Vaamonde [Espagne] ; M. R. Luquin [Espagne] ; Obeso [Espagne]Source :
- Movement Disorders [ 0885-3185 ] ; 1990.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Administration, Oral, Adult, Aged, Antiparkinson agent, Apomorphine (therapeutic use), Brain, Corpus striatum, Degenerative disease, Dopa, Dopamine agonist, Dopamine receptor, Dopaminergic response, Dopaminergic transmission, Drug Tolerance, Drug combination, Ergolines (administration & dosage), Human, Humans, Infusion Pumps, Intravenous apomorphine, Levodopa (administration & dosage), Levodopa (therapeutic use), Lisuride (administration & dosage), Lisuride (therapeutic use), Lisuride infusion, Middle Aged, Movement Disorders (drug therapy), Movement Disorders (etiology), Nervous system diseases, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson disease, Regulation(control), Tolerance.
- MESH :
- chemical , administration & dosage : Ergolines, Levodopa, Lisuride.
- chemical , therapeutic use : Apomorphine, Levodopa, Lisuride.
- complications : Parkinson Disease.
- drug therapy : Movement Disorders, Parkinson Disease.
- etiology : Movement Disorders.
- Administration, Oral, Adult, Aged, Drug Tolerance, Humans, Infusion Pumps, Middle Aged.
Abstract
The aim of this study was to assess whether or not continuous infusion of lisuride in combination with intermittent levodopa‐carbidopa administration was associated with tolerance. Intravenous apomorphine was given to four patients before initiation of chronic treatment with subcutaneous lisuride infusion and oral levodopa. The study was repeated under identical conditions after a mean of 18 months of treatment. In no case was the motor response induced by apomorphine infusion reduced as compared to baseline assessment. Choreic dyskinesias accompanying the “on” state were enhanced in all patients. These findings suggest that chronic continuous infusion of a dopamine agonist like lisuride, associated with oral levodopa, is not accompanied by tolerance or down‐regulation of striatal dopaminergic receptors.
Url:
DOI: 10.1002/mds.870050316
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003704
- to stream Istex, to step Curation: 003704
- to stream Istex, to step Checkpoint: 004418
- to stream PubMed, to step Corpus: 004E62
- to stream PubMed, to step Curation: 004E62
- to stream PubMed, to step Checkpoint: 004F20
- to stream Ncbi, to step Merge: 003C78
- to stream Ncbi, to step Curation: 003C78
- to stream Ncbi, to step Checkpoint: 003C78
- to stream Main, to step Merge: 009663
- to stream PascalFrancis, to step Corpus: 003918
- to stream PascalFrancis, to step Curation: 002F07
- to stream PascalFrancis, to step Checkpoint: 003955
- to stream Main, to step Merge: 009731
- to stream Main, to step Curation: 006329
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease</title><author><name sortKey="Vaamonde, J" sort="Vaamonde, J" uniqKey="Vaamonde J" first="J." last="Vaamonde">J. Vaamonde</name></author><author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name></author><author><name sortKey="Obeso" sort="Obeso" uniqKey="Obeso" last="Obeso">Obeso</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3DBD4C7FF06C50063CA0A02EE09C0364648EBFFA</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1002/mds.870050316</idno><idno type="url">https://api.istex.fr/document/3DBD4C7FF06C50063CA0A02EE09C0364648EBFFA/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003704</idno><idno type="wicri:Area/Istex/Curation">003704</idno><idno type="wicri:Area/Istex/Checkpoint">004418</idno><idno type="wicri:doubleKey">0885-3185:1990:Vaamonde J:dopaminergic:responsiveness:to</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:2388647</idno><idno type="wicri:Area/PubMed/Corpus">004E62</idno><idno type="wicri:Area/PubMed/Curation">004E62</idno><idno type="wicri:Area/PubMed/Checkpoint">004F20</idno><idno type="wicri:Area/Ncbi/Merge">003C78</idno><idno type="wicri:Area/Ncbi/Curation">003C78</idno><idno type="wicri:Area/Ncbi/Checkpoint">003C78</idno><idno type="wicri:doubleKey">0885-3185:1990:Vaamonde J:dopaminergic:responsiveness:to</idno><idno type="wicri:Area/Main/Merge">009663</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:91-0247282</idno><idno type="wicri:Area/PascalFrancis/Corpus">003918</idno><idno type="wicri:Area/PascalFrancis/Curation">002F07</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003955</idno><idno type="wicri:doubleKey">0885-3185:1990:Vaamonde J:dopaminergic:responsiveness:to</idno><idno type="wicri:Area/Main/Merge">009731</idno><idno type="wicri:Area/Main/Curation">006329</idno><idno type="wicri:Area/Main/Exploration">006329</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease</title><author><name sortKey="Vaamonde, J" sort="Vaamonde, J" uniqKey="Vaamonde J" first="J." last="Vaamonde">J. Vaamonde</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Department of Neurology, Clinica Universitaria, University of Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Department of Neurology, Clinica Universitaria, University of Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Obeso" sort="Obeso" uniqKey="Obeso" last="Obeso">Obeso</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Department of Neurology, Clinica Universitaria, University of Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1990">1990</date><biblScope unit="vol">5</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="260">260</biblScope><biblScope unit="page" to="262">262</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">3DBD4C7FF06C50063CA0A02EE09C0364648EBFFA</idno><idno type="DOI">10.1002/mds.870050316</idno><idno type="ArticleID">MDS870050316</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Antiparkinson agent</term><term>Apomorphine (therapeutic use)</term><term>Brain</term><term>Corpus striatum</term><term>Degenerative disease</term><term>Dopa</term><term>Dopamine agonist</term><term>Dopamine receptor</term><term>Dopaminergic response</term><term>Dopaminergic transmission</term><term>Drug Tolerance</term><term>Drug combination</term><term>Ergolines (administration & dosage)</term><term>Human</term><term>Humans</term><term>Infusion Pumps</term><term>Intravenous apomorphine</term><term>Levodopa (administration & dosage)</term><term>Levodopa (therapeutic use)</term><term>Lisuride (administration & dosage)</term><term>Lisuride (therapeutic use)</term><term>Lisuride infusion</term><term>Middle Aged</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Nervous system diseases</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Regulation(control)</term><term>Tolerance</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Ergolines</term><term>Levodopa</term><term>Lisuride</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Apomorphine</term><term>Levodopa</term><term>Lisuride</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Drug Tolerance</term><term>Humans</term><term>Infusion Pumps</term><term>Middle Aged</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term><term>Association médicamenteuse</term><term>Corps strié</term><term>Dopa</term><term>Encéphale</term><term>Homme</term><term>Lisuride</term><term>Maladie dégénérative</term><term>Parkinson maladie</term><term>Récepteur dopaminergique</term><term>Régulation</term><term>Stimulant dopaminergique</term><term>Système nerveux pathologie</term><term>Tolérance</term><term>Transmission dopaminergique</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to assess whether or not continuous infusion of lisuride in combination with intermittent levodopa‐carbidopa administration was associated with tolerance. Intravenous apomorphine was given to four patients before initiation of chronic treatment with subcutaneous lisuride infusion and oral levodopa. The study was repeated under identical conditions after a mean of 18 months of treatment. In no case was the motor response induced by apomorphine infusion reduced as compared to baseline assessment. Choreic dyskinesias accompanying the “on” state were enhanced in all patients. These findings suggest that chronic continuous infusion of a dopamine agonist like lisuride, associated with oral levodopa, is not accompanied by tolerance or down‐regulation of striatal dopaminergic receptors.</div></front></TEI><affiliations><list><country><li>Espagne</li></country></list><tree><country name="Espagne"><noRegion><name sortKey="Vaamonde, J" sort="Vaamonde, J" uniqKey="Vaamonde J" first="J." last="Vaamonde">J. Vaamonde</name></noRegion><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name><name sortKey="Obeso" sort="Obeso" uniqKey="Obeso" last="Obeso">Obeso</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006329 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006329 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3DBD4C7FF06C50063CA0A02EE09C0364648EBFFA
|texte= Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |